- Home
- ZKH vs ERAS Comparison
ZKH vs ERAS Comparison
Compare ZKH & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZKH
- ERAS
- Stock Information
- Founded
- ZKH 1998
- ERAS 2018
- Country
- ZKH China
- ERAS United States
- Employees
- ZKH N/A
- ERAS N/A
- Industry
- ZKH
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- ZKH
- ERAS Health Care
- Exchange
- ZKH Nasdaq
- ERAS Nasdaq
- Market Cap
- ZKH 441.7M
- ERAS 396.6M
- IPO Year
- ZKH 2023
- ERAS 2021
- Fundamental
- Price
- ZKH $2.77
- ERAS $1.39
- Analyst Decision
- ZKH Buy
- ERAS Strong Buy
- Analyst Count
- ZKH 1
- ERAS 6
- Target Price
- ZKH $4.00
- ERAS $4.83
- AVG Volume (30 Days)
- ZKH 28.1K
- ERAS 1.4M
- Earning Date
- ZKH 05-20-2025
- ERAS 05-20-2025
- Dividend Yield
- ZKH N/A
- ERAS N/A
- EPS Growth
- ZKH N/A
- ERAS N/A
- EPS
- ZKH N/A
- ERAS N/A
- Revenue
- ZKH $1,200,328,532.00
- ERAS N/A
- Revenue This Year
- ZKH $11.95
- ERAS N/A
- Revenue Next Year
- ZKH $11.23
- ERAS N/A
- P/E Ratio
- ZKH N/A
- ERAS N/A
- Revenue Growth
- ZKH 0.46
- ERAS N/A
- 52 Week Low
- ZKH $2.55
- ERAS $1.01
- 52 Week High
- ZKH $13.97
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- ZKH 37.57
- ERAS 51.46
- Support Level
- ZKH $2.60
- ERAS $1.37
- Resistance Level
- ZKH $2.91
- ERAS $1.61
- Average True Range (ATR)
- ZKH 0.16
- ERAS 0.14
- MACD
- ZKH 0.02
- ERAS 0.00
- Stochastic Oscillator
- ZKH 56.41
- ERAS 45.68
About ZKH ZKH Group Limited each representing thirty-five (35)
ZKH Group Ltd engages in providing MRO procurement service platform in China. It provides one-stop MRO procurement and management services for its customers, and offers digital and fulfillment solutions for participants along the industry value chain. It offers a broad range of MRO product offerings covering all MRO product lines on its platform, including spare parts, chemicals, manufacturing parts, general consumables, and office supplies. All of the Group's revenues are derived from the PRC.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.